Loading...
Loading...
HUMA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 1.8M |
| Gross Profit | -1.8M |
| Operating Expense | 27.7M |
| Operating I/L | -29.5M |
| Other Income/Expense | -27.2M |
| Interest Income | 1.3M |
| Pretax | -56.7M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -56.7M |
Humacyte, Inc. specializes in developing and manufacturing bioengineered human tissues for various medical applications. The company's proprietary technology platform enables the production of human acellular vessels (HAVs) designed for easy implantation without triggering immune rejection. These investigational HAVs target the vascular repair, reconstruction, and replacement market, including applications in vascular trauma, hemodialysis access, peripheral arterial disease, and coronary artery bypass grafting. Additionally, the company is working on HAVs for pediatric heart surgery and cellular therapy delivery, such as pancreatic islet cell transplantation for Type 1 diabetes treatment.
